ER POSITIVE, HER2 POSITIVE BREAST CANCER
Clinical trials for ER POSITIVE, HER2 POSITIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new ER POSITIVE, HER2 POSITIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for ER POSITIVE, HER2 POSITIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for hard-to-treat breast cancer: drug combo targets triple positive tumors
Disease control Recruiting nowThis study tests a new drug called elacestrant, combined with two standard biologic therapies, in people with advanced triple positive breast cancer (ER+, PR+, HER2+). The goal is to see if the combination can slow or stop cancer growth. About 50 women aged 18 and older will take…
Matched conditions: ER POSITIVE, HER2 POSITIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: NYU Langone Health • Aim: Disease control
Last updated Jun 18, 2026 11:49 UTC
-
New hope for advanced breast cancer: umbrella trial tests multiple drug combos
Disease control Recruiting nowThis study is for people with advanced ER-positive breast cancer that has stopped responding to standard treatments. It tests several new drug combinations to see which ones work best and are safe. About 316 participants will be assigned to different treatment groups based on the…
Matched conditions: ER POSITIVE, HER2 POSITIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 18, 2026 11:46 UTC